Identitication of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension

被引:14
作者
Pinon, GM
Fagart, J
Souque, A
Auzou, G
Vandewalle, A
Rafestin-Oblin, ME
机构
[1] Univ Paris 07, INSERM 478, F-75870 Paris 18, France
[2] INSERM, U540, F-34090 Montpellier, France
关键词
aldosterone; nuclear receptor; hypertension;
D O I
10.1016/j.mce.2003.10.053
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ability of steroid ligands to inactivate the human mineralocorticoid receptor (MRWT) has been shown to be due to their inability to contact Asn770. a residue of the H3 helix involved in stabilizing contacts with the H11-H12 loop region. However, all steroid ligands that display antagonist properties when bound to MRWT, have been shown to activate a mutant receptor (MRL810) associated with a severe form of hypertension. Biochemical studies revealed that S810L mutation induces a change in the receptor conformation and increases the steroid-receptor complexes stability. From a three-dimensional model of the MR ligand-binding domain, it is likely that the S810L mutation causes a steric hindrance between the side chains of Leu810 (H5) and Gln776 (H3) that provokes a bending of the H3 helix. As a consequence, the positioning of MRWT antagonists within the ligand-binding cavity is modified in such a way that they can activate the mutant MRL810. The results from biochemical studies also revealed that 5alpha-pregnan-20-one, 4,9-androstadiene-3,17-dione and RU486, unable to bind MRWT, acted as potent MRL810 antagonists. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 23 条
[1]   A single amino acid mutation of Ala-773 in the mineralocorticoid receptor confers agonist properties to 11β-substituted spirolactones [J].
Auzou, G ;
Fagart, J ;
Souque, A ;
Hellal-Lévy, C ;
Wurtz, JM ;
Moras, D ;
Rafestin-Oblin, ME .
MOLECULAR PHARMACOLOGY, 2000, 58 (04) :684-691
[2]   Glucocorticoid metabolism by 11-β hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity [J].
Bocchi, B ;
Fagart, J ;
Cluzeaud, F ;
Fay, M ;
Rafestin-Oblin, ME ;
Farman, N .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 84 (2-3) :239-244
[3]   Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications [J].
Bourguet, W ;
Germain, P ;
Gronemeyer, H .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (10) :381-388
[4]  
Cadepond F, 1997, ANNU REV MED, V48, P129
[5]   STATISTICAL TEST OF MODELS AND COMPUTERIZED PARAMETER-ESTIMATION FOR ALDOSTERONE BINDING IN RAT-KIDNEY [J].
CLAIRE, M ;
RAFESTINOBLIN, ME ;
MICHAUD, A ;
CORVOL, P ;
VENOT, A ;
ROTHMEYER, C ;
BOISVIEUX, JF ;
MALLET, A .
FEBS LETTERS, 1978, 88 (02) :295-299
[6]   SYNTHESIS OF NEW 11-BETA-SUBSTITUTED SPIROLACTONE DERIVATIVES - RELATIONSHIP WITH AFFINITY FOR MINERALOCORTICOID AND GLUCOCORTICOID RECEPTORS [J].
CLAIRE, M ;
FARAJ, H ;
GRASSY, G ;
AUMELAS, A ;
RONDOT, A ;
AUZOU, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (16) :2404-2407
[7]   MECHANISM OF THE ANTI-MINERALOCORTICOID EFFECTS OF SPIROLACTONES [J].
CORVOL, P ;
CLAIRE, M ;
OBLIN, ME ;
GEERING, K ;
ROSSIER, B .
KIDNEY INTERNATIONAL, 1981, 20 (01) :1-6
[8]   FIREFLY LUCIFERASE GENE - STRUCTURE AND EXPRESSION IN MAMMALIAN-CELLS [J].
DEWET, JR ;
WOOD, KV ;
DELUCA, M ;
HELINSKI, DR ;
SUBRAMANI, S .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (02) :725-737
[9]   THE STEROID AND THYROID-HORMONE RECEPTOR SUPERFAMILY [J].
EVANS, RM .
SCIENCE, 1988, 240 (4854) :889-895
[10]   Antagonism in the human mineralocorticoid receptor [J].
Fagart, J ;
Wurtz, JM ;
Souque, A ;
Hellal-Levy, C ;
Moras, D ;
Rafestin-Oblin, ME .
EMBO JOURNAL, 1998, 17 (12) :3317-3325